UNSPSC 51384614: Mofebutazone

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C13H16N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SPW36WUI5Z, chemically known as 3,5-pyrazolidinedione, 4-butyl-1-phenyl- but generally known as mofebutazone, which bears US NIH Compound Identifier 16639. European Medicines Agency schedules Mofebutazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09033MIG. The term MOFEBUTAZONE is an International Non-Proprietary Name.

UNSPSC 51384614 Mofebutazone, a Commodity-tier code, shows minimal alignment with recent state and local procurement activity. The three most recent opportunities posted under this code involve naloxone and drug deactivation systems procurement, a pharmacy benefit program initiative exploring direct-to-manufacturer prescriptions, and a multistate cooperative purchasing contract for generic pharmaceuticals and over-the-counter products—none of which involve mofebutazone, an anti-inflammatory veterinary and equine pharmaceutical. The mismatch suggests either miscoding in the source data or that mofebutazone procurement through state and local channels is not currently active.

The issuing bodies documented include a county health department (Seminole County, Florida), a state health and human services agency (Texas HHS Commission), and a multistate cooperative purchasing alliance (MMCAP, administered by Minnesota Department of Administration). Geographic activity spans Florida, Texas, and the MMCAP states including Minnesota and Oregon. Recent opportunities include Seminole County's IFB60459723LAS for naloxone and drug deactivation systems with quarterly deliveries and a July 26, 2023 response date; Texas HHS Commission's RFI HHS0017013 on direct-to-manufacturer prescription programs posted April 3, 2026; and MMCAP's RFP S1070000015802 for generic pharmaceuticals and OTC products with proposals due March 26, 2026. No recent solicitations specifically naming mofebutazone or related equine or veterinary anti-inflammatory products appear in the available records for state and local procurement.